We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Macquarie on Tata Motors: Outperform| Target Rs 1,028
Macquarie maintained an outperform rating on Tata Motors with a target price of Rs 1,028. Pure play structure is likely to drive better value discovery.The conglomerate structure was constraining valuation upside. The Pure-play structure lends investment flexibility to investors.
PV segment valuation discount to Maruti could narrow if Tata delivers on market-share gains/better margins.
JPMorgan on Max Healthcare: Overweight| Target Rs 888
JPMorgan maintained an overweight rating on Max Healthcare with a target price of Rs 888. Max Healthcare is a high-conviction idea. The stock is available at an attractive entry level and the growth prospects remain intact.
The global investment bank believes that the SC directive will be difficult to implement and hence recommends investors use this weakness as a buying opportunity.
The stock trades at an attractive valuation of 24x FY26E EBITDA, a ~20% premium to the sector average, and a ~10% discount to Medanta.
Jefferies on IIFL Finance: Buy| Target Rs 765
Jefferies maintained a buy rating on IIFL Finance with a target price of Rs 765. The Reserve Bank of India (RBI) restricts disbursing Gold Loans.
There is a potential risk to earnings if restrictions are prolonged. If the gold lending ban stays for 9 months, we est. EPS impact can be over 25-30%, said the note.
UBS on Siemens: Neutral| Target Rs 5,000
UBS maintained a neutral rating on Siemens but raised the target price to Rs 5,000 from Rs 3,750 earlier.
Large project orders to stay strong and the transmission segment looks promising. Capacity expansion by incumbent leaders including Siemens.
Weakness in short-cycle orders is transient; medium-term prospects remain firm. Electrification portfolio on a rising trajectory
The global investment bank raised the target price as the large order pipeline improved.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
